Oops. Pfiz­er's CDK 4/6 block­buster Ibrance flunks the OS mark for breast can­cer

Just weeks af­ter No­var­tis $NVS set out to bur­nish its prospects in breast can­cer with promis­ing pro­gres­sive-free sur­vival num­bers for Kisqali and ful­ves­trant in treat­ing pa­tients with HR+/HER2- ad­vanced breast can­cer, ri­val Pfiz­er $PFE has some con­fess­ing to do to­day about its block­buster mar­ket-lead­ing duo us­ing Ibrance.

Pfiz­er’s com­bo us­ing ful­ves­trant failed to achieve sta­tis­ti­cal sig­nif­i­cance for over­all sur­vival in PALO­MA-3, which will like­ly give the com­pe­ti­tion a se­ri­ous leg up as they try to play catch-up. Ibrance is one of three key CDK 4/6 drugs on the mar­ket, in­clud­ing Kisqali and Eli Lil­ly’s $LLY Verzenio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.